Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.48 |
| ▸ | NPY1R | P25929 | 5/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | NRP1 | O14786 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806494 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30016402 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL32932019 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30017192 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL1067832 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30528148 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL288961 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL15263299 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL31694501 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL15263305 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521359-A | Polypeptide nanoparticle composition | 深圳厚存纳米药业有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-109196004-B | Engineered scaffold for vascularized tissue repair | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | claimed |
| US-20040067890-A1 | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions | GUPTA SHYAM K (US) | 2004-04-08 | — | — | US | claimed |
| US-5811401-A | Advanced glycosylation endproducts and methods of use therefor | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-22 | — | — | US | claimed |
| CN-119709844-B | Application of rice gene OsbHLH176,176 in regulation and control of cold resistance | 南京农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| CN-115873803-B | Method for improving NK cell survival and anti-tumor activity and application thereof | 上海恩凯细胞技术有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119709844-A | Application of rice gene OsbHLH176,176 in regulation and control of cold resistance | 南京农业大学 | 2025-03-28 | — | — | CN | disclosed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-117210441-B | Low-temperature salt-tolerant beta-glucosidase and application thereof in conversion of ginsenoside Rb1 | 云南师范大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-118401257-A | Methods for producing antibody peptide conjugates | 美国安进公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20050085540-A1 | Vasodilation; anticoagulants; thrombosis; antiproliferative agents ; angiogenesis inhibitors; drug delivery; bioavailability; oral administering | UNITED THERAPEUTICS CORPORATION | 2005-04-21 | — | — | US | disclosed |
| WO-2005007081-A2 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040067890-A1 | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions | GUPTA SHYAM K (US) | 2004-04-08 | — | — | US | disclosed |
| EP-0346460-B1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION | CO PHARMA CORPORATION (IT) | 1993-03-10 | — | — | EP | disclosed |
| US-5110798-A | Immunomodulators for bone marrow transplants | CO PHARMA CORPORATION S.R.L. (IT) | 1992-05-05 | — | — | US | disclosed |
| EP-0346460-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION. | CO PHARMA CORP SRL (IT) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989005818-A1 | PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION | CO PHARMA CORPORATION S.R.L. (IT) | 1989-06-29 | — | — | WO | disclosed |
| US-4457907-A | Composition and method for protecting a therapeutic drug | CLEAR LAKE DEVELOPMENT GROUP (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
| US-20050085540-A1 | Vasodilation; anticoagulants; thrombosis; antiproliferative agents ; angiogenesis inhibitors; drug delivery; bioavailability; oral administering | PTGIS, PGF, PLAT | NPY4R 1671/4885NPY1R 902/4885NPY2R 1374/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.